Neoadjuvant Chemotherapy with Docetaxel and Adriamycin in Breast Cancer; Clincopathologic Factors Influencing to Response Rate

Dong Won Ryu; Chang Wan Jun; Chung Han Lee

doi:10.4048/jbc.2008.11.2.89

Journal List > J Breast Cancer > v.11(2) > 1036128

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Ryu, Jun, and Lee: Neoadjuvant Chemotherapy with Docetaxel and Adriamycin in Breast Cancer; Clincopathologic Factors Influencing to Response Rate

Original Article

Journal of Breast Cancer

Journal of Breast Cancer 2008; 11(2): 89-94.

Published online: 30 June 2008

DOI: https://doi.org/10.4048/jbc.2008.11.2.89

Neoadjuvant Chemotherapy with Docetaxel and Adriamycin in Breast Cancer; Clincopathologic Factors Influencing to Response Rate

Dong Won Ryu, Chang Wan Jun, Chung Han Lee

Department of Surgery, Kosin University Medical School, Busan, Korea.

surgeons@paran.com

Received 13 September 2007 Accepted 2 May 2008

Abstract

Purpose

The objective of this study was to test the efficacy and toxicity of adriamycin plus docetaxel as the primary chemotherapy for women with advanced breast carcinoma, and including those patients with inflammatory breast cancer. Our study also evaluated the clinicopathologic factors influencing the response rate to neoadjuvant chemotherapy.

Methods

Twenty-eight patients who underwent neoadjuvant chemotherapy between 2002 and 2004 were included for this study. The patients were treated with adriamycin (50 mg/m²; intravenous bolus) followed by docetaxel (75 mg/m²; 1-hr intravenous infusion) on the first day of each cycle for an average four cycles. We analysed the response rate to adjuvant chemotherapy by reviewing the post operative pathologic report. Additionally we compared the clincopathologic factors related to the response rate. Statistical analyses were performed with χ²-tests and using SPSS 11.0.

Results

The mean age at diagnosis was 48.9 yr old (range 29-63 yr). The tumoral response to neoadjuvant chemotherapy was, 3 patients (10.7%) showed a complete response (CR), 21 patients (75%) showed a partial response (PR). and which about lymph node were that 15 patients (75%) have shown responder, 5 patients (25%) have shown non-responder. The overall response rate to neoadjuvant chemotherapy was 85.7%. The preoperative serum-CEA level was influenced the response rate to neoadjuvant chemotherapy (p=0.025). Grade 3 or 4 neutropenia was recorded in 81.9% of the patients (N=59/72). Grade 3 or 4 anemia was recorded in 2.8% of the patients.

Conclusion

Neoadjuvant chemotherapy with adriamycin plus docetaxel was effective treatment for patients with locally advanced breast cancer. The preoperative serum CEA level colud be the important factor for the neoadjuvant chemotherapy response rate.

Keywords: Neoadjuvant chemotherapy, Locally advanced breast cancer, Response rate, Serum CEA level

Figures and Tables

Table 1

Patient characteristics

CTx=chemotherapy.

Table 2

Response rate of tumor size and lymph node after neoadjuvant chemotherapy

CR=complete response; PR=partial response; SD=stable disease; PD=progressive disease.

Table 3

Clinicopathologic factors influencing to tumoral response rate after chemotherapy

CR=complete response; PR=partial response; SD=stable disease; ER=estrogen receptor; PgR=progesterone receptor; EIC=extensive intraductal component.

Table 4

Clincopathologic factors influencing to nodal response rate after neoadjuvant chemotherapy

ER=estrogen receptor; PgR=progesterone receptor; EIC=extensive intraductal component.

Table 5

Toxicity of neoadjuvant chemotherapy

References

1. Lee SI, Lee CJ, Choi JH, Kim JR, Chang ES. Short term effect of neoadjuvant therapy with docetaxel and adriamycin in advanced breast cancer. J Korean Breast Cancer Soc. 2003. 6:189–195.

2. Bae JM, Won YJ, Jung KW, Suh KA, Ahn DH, Park JC. Annual report of the central cancer registery in Korea-1999; based on registered date from 128 hospitals. Cancer Res Treat. 2001. 33:367–372.

3. Osborne CK, Ravdin PM. Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Adjuvant systemic therapy of primary breast cancer. Disease of the breast. 2000. second ed. Philadelphia: Lippincott williams and Wilkins;599–632.

4. Ministry of Health and Welfare, Republic of Korea. Annual report of cancer registry program in the Republic of Korea. 1998.1.1.-1998. 12.31.

5. Ko SS, Lee IK, Kim SK, Kim SI, Park BW, Lee KS. Neoadjuvant chemotherapy for the local advanced breast cancer. J Korean Breast Cancer Soc. 2002. 5:311–318.

6. Abeloff MD, Lichter AS, Niederhuber JE. Abeloff MD, Armitage JO, editors. Breast. Clinical Oncology. 2000. second ed. Philadelphia: Churchil Livingstone;2051–2059.

7. Hunt KK, Ames FC, Singletary SE, Buzdar AU, Hortobagyi GN. Locally advanced noninflammtory breast cancer. Sur Clin North Am. 1996. 76:393–410.

8. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer; An overview of the randomised trials. Lancet. 1998. 352:930–942.

9. Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 1987. 47:3889–3894.

10. National Institutes of Health Consensus Development Panel. National Institues of Health Consensud Development Statement: Adjuvant therapy for Breast Cancer, November 1-3, 2000. J Natl Cancer Inst. 2001. 93:979–989.

11. Hobar PC, Jones RC, Schouten J, Leitch AM, Hendler F. Multimodality treatment of locally advanced breast carcinoma. Arch Surg. 1988. 123:951–955.

12. Hortobagyi GN, Singletary SE, Stroma EA. Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Treatment of Locally advanced and inflammatory breast cancer. Disease of the breast. 2000. second ed. Philadelphia: Lippincott Williams and Wilkins;645–660.

13. Buzdar AU, Singletary SE, Theriault RL. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with opearable breast cancer. J Clin Oncol. 1999. 17:3412–3479.

14. Merajver SD, Weber BL, Cody R. Breast conservation and prolonged chemotherapy for locally advanced breast cancer. The university of Michigan experience. J Clin Oncol. 1997. 15:2873–2885.

15. Fisher B, Bryant J, Wolmark N. Effecto of preoperative chemotherapy on the outcome of women with opearable breast cancer. J Clin Oncol. 1998. 16:2672–2685.

16. Kuerer HM, Newman LA, Smith TL. Clincal course of breast cancer patients with pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999. 17:460–469.

17. Korea Breast Cancer Society. Korea breast cancer data of 1997. J Korea Cancer Assoc. 1999. 31:1202–1209.

18. Zucali R, Uslenghi C, Kenda R, Bonadonna G. Natral history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer. 1976. 37:1442–1431.

19. Lopez MJ, Andriole DP, Kraybill WG, Khojasteh A. Multimodal therapy in locally advanced breast carcinoma. Am J Surg. 1990. 160:669–674.

20. Lee SH, Lee KS, Min JS, Lee KP, Kim BS, Koh EH. Preoperative chemotherapy in locally advanced breast cancer. J Korean Sug Soc. 1990. 38:34–39.

21. Park BW, Lee WJ, Lee KS. Induction chemotherapy in locally advanced breast cancer. J Korean Surg Soc. 1994. 47:616–622.

TOOLS

Similar articles